Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B‐Cell Lymphoma

Schuster, S.; Bishop, M.; Tam, C.; Waller, E.; Borchmann, P.; Mcguirk, J.; Jäger, U.; Jaglowski, S.; Andreadis, C.; Westin, J.; Fleury, I.; Bachanova, V.; Foley, R.; Ho, J.; Mielke, S.; Magenau, J.; Holte, H.; Pantano, Serafino; Pacaud, L.; Awasthi, R.; Chu, J.; Anak, Ö.; Salles, G.; Maziarz, R.

doi:10.1056/NEJMoa1804980

Public

Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B‐Cell Lymphoma

Shared by NobleBlocks on Jan 3, 2019 • 12:00 AM UTC

Authors:

S. Schuster

M. Bishop

C. Tam

Abstract

BACKGROUND Patients with diffuse large B‐cell lymphoma that is refractory to primary and second‐line therapies or that has relapsed after stem‐cell transplantation have a poor prognosis. The chimeric antigen receptor (CAR) T‐cell therapy tisagenlecleucel targets and eliminates CD19‐expressing B cell...

Subject

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!